Amazing AI PLC Announces Bitcoin Treasury Policy Update
LONDON, GB / / June 27, 2025 / Amazing AI plc (AQSE: AI) - AAI, a global fintech group specialising in online consumer loans, announces an update to its Bitcoin Treasury Policy. AAI is in discussions with one of the world's largest regulated custodians of bitcoin who are highly experienced in setting up Bitcoin Treasuries and act for over 1,500 institutional clients in over 50 countries and hold over 100 billion USD of assets on their platform as custodian. AAI's proposed custodian, which has the ability to buy at lower spreads over-the-counter compared to crypto exchanges, will facilitate all purchases of bitcoin and provide secure cold wallet storage for AAI's bitcoin, avoiding crypto exchange hot wallet risk.
Once engaged, the custodian will be able to provide financing against AAI's bitcoin providing AAI with the benefit of any appreciation in the value of the Bitcoin whilst also allowing it to leverage its bitcoin asset 50%. This can then be used to drive greater lending resources in its USA lending operation, which currently charges 59.9% per annum in the state of Georgia, and, in turn, revenues and profits. By way of example, if AAI was able to purchase £20 million of bitcoin in its Bitcoin Treasury, it could potentially borrow up to £10 million to lend out to consumers in Georgia, USA which the Board anticipate could be able to generate up to £5.99 million in additional recurring revenue to AAI per annum.
In addition, AAI is currently incorporating a 100% owned subsidiary company in the bitcoin friendly jurisdiction of Mauritius. This entity will serve a dual purpose for both acting as the entity that will buy and hold bitcoin and for potential future expansion into consumer lending emerging markets utilising fiat.
The Company will continue to focus on delivering its organic growth strategy centered on consumer lending and on exploring AI finance related services whilst growing a bitcoin treasury over the shorter-term. The Company intends to strategically allocate capital generated from its business operations and future fundraisings, with the aim of maintaining a treasury consisting of both traditional cash reserves and bitcoin.
The Company is exploring potential fundraising opportunities for this purpose, following which, the Directors anticipate being in a position to commence bitcoin acquisitions in July 2025.
Relevant material changes to its bitcoin treasury holdings and further updates on the Bitcoin Treasury Policy will be announced by the Company in a timely manner.
Paul Mathieson, CEO of Amazing AI plc said,"The key difference between Amazing AI plc and most other companies with Bitcoin Treasuries is that we have an underlying consumer loans business that will be able to leverage up the benefits of Bitcoin Treasury by utilising borrowed funds against our Bitcoin Treasury to increase revenue growth in our existing US lending business, future potential Philippines and African lending businesses and our best-of-breed AI finance related services business."
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company accept responsibility for the contents of this announcement.
Enquiries:
Amazing AI plc
Paul Mathieson - Chief Executive Officer
iecenquiries@investmentevolution.com
Cairn Financial Advisers LLP (AAI Corporate Adviser)
Ludovico Lazzaretti
+44 (0) 20 7213 0880
Jo Turner
Oberon Capital (AAI Corporate Broker)
Adam PollockNick LoveringJessica Cave
+44 (0) 203 179 5300
Professional/institutional investors can contact Oberon Capital on corporatesales@oberoninvestments.com
About Amazing AI plcAmazing AI plc (AAI) is an AI driven, consumer finance fintech innovator that leverages its regulated licensed lending and collections operations, experience and network to distribute best-of-breed AI finance related services globally, specifically focused on lending, collections and debt financing services. AAI operates under the consumer brand Mr. Amazing Loans in the United States with state consumer lending licenses/certificates of authority and an established track-record of lending, collections and regulatory compliance for over 14 years. AAI intends to investigate further utilisation of AI in its own US consumer lending operational processes and seek additional strategic collaborations, joint ventures and acquisitions in the AI sector globally, including in AI deception detection services to increase underwriting and collections performance. AAI also plans to investigate the potential to conduct its own enhanced product/service development, territory customisation and new service initiatives.
For more information please visit: www.investmentevolution.com/investors
Important Notices
Amazing AI plc (the "Company") intends to hold treasury reserves and surplus cash in bitcoin. Bitcoin is a type of cryptocurrency or crypto asset. Whilst the Board of Directors of the Company considers holding bitcoin to be in the best interests of the Company, the Board remains aware that the financial regulator in the UK (the "Financial Conduct Authority" or "FCA") considers investment in bitcoin to be high risk. At the outset, it is important to note that an investment in the Company is not an investment in bitcoin, either directly or by proxy. However, the Board of Directors of the Company consider bitcoin to be an appropriate store of value and growth for the Company's reserves and, accordingly, the Company is materially exposed to bitcoin. Such an approach is innovative, and the Board of Directors of the Company wish to be clear and transparent with prospective and actual investors in the Company on the Company's position in this regard.
The Company is neither authorised nor regulated by the FCA and cryptocurrencies (such as bitcoin) are unregulated in the UK. As with most other investments, the value of bitcoin can go down as well as up, and therefore the value of bitcoin holdings can fluctuate. The Company may not be able to realise any future bitcoin exposure for the same as it paid in the first place or even for the value the Company ascribes to bitcoin positions due to these market movements. As bitcoin is unregulated, the Company is not protected by the UK's Financial Ombudsman Service or the Financial Services Compensation Scheme.
Nevertheless, the Board of Directors of the Company has taken the decision to invest in bitcoin, and in doing so is mindful of the special risks bitcoin presents to the Company's financial position. These risks include (but are not limited to): (i) the value of bitcoin can be highly volatile, with value dropping as quickly as it can rise. Investors in bitcoin must be prepared to lose all money invested in bitcoin; (ii) the bitcoin market is largely unregulated. There is a risk of losing money due to risks such as cyber-attacks, financial crime and counterparty failure; (iii) the Company may not be able to sell bitcoin at will. The ability to sell bitcoin depends on various factors, including the supply and demand in the market at the relevant time. Operational failings such as technology outages, cyber-attacks and comingling of funds could cause unwanted delay; and (iv) crypto assets are characterised in some quarters by high degrees of fraud, money laundering and financial crime. In addition, there is a perception in some quarters that cyber-attacks are prominent which can lead to theft of holdings or ransom demands. The Board of Directors of the Company does not subscribe to such a negative view, especially in relation to bitcoin. However, prospective investors in the Company are encouraged to do their own research before investing.
Caution Regarding Forward Looking StatementsCertain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not a guarantee of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Amazing AI PLC
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?
Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for Bristol-Myers Squibb shares, but what is the fundamental picture for the company? Currently, Bristol-Myers Squibb is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 36% of our Zacks Industry Rank. Over the last 60 days, one analyst increased the earnings estimates for the current quarter, while three have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.66 per share to $1.53 in that period. Given the way analysts feel about Bristol-Myers Squibb right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
35 minutes ago
- Yahoo
1 sneaky UK growth stock to consider in July
Growth stocks come in all shares and sizes. You've obviously got the likes of Nvidia (NVDA), with its eye-popping growth rates, or Rolls-Royce (RR.L), which has positively transformed its profit margins. Then there's WH Smith (SMWH.L), which is a UK stock that may raise a few eyebrows when associated with growth. After all, many people might still associate the company with its high street stores, the first of which opened in London in 1792. But, sadly, there isn't much growth happening today on British high streets. E-commerce and high taxes are doing the irreversible damage there. In March, WH Smith announced it would sell its 480 high street shops to Modella Capital for £52m in gross cash proceeds. However, it announced today (30 June) that it now expects up to £40m. This will be made up of £10m expected in FY25, up to £20m in FY26, and £10m of deferred tax assets to be realised later. In other words, it's accepting £12m less to get the deal done, after a recent period of softer trading forced Modella to renegotiate the original deal. In response, the WH Smith share price dropped as much as 5% today, before clawing back some losses. It's now trading 2.5% lower at 1,100p. Here's why I think this FTSE 250 (^FTMC) stock is worth considering at this price. This transaction now positions WH Smith, which is keeping its brand, as a travel retailer. As the company puts it, 'This creates a pure play global travel retailer which is well positioned to capture the substantial global growth opportunities in its key markets and drive enhanced shareholder value'. Unlike the falling footfall and unappealing economics of the high street, global travel is a structural growth market. Over the next couple of decades, global airport passenger numbers are expected to double, and that will need a lot of investment in airport infrastructure. WH Smith already operates around 1,300 stores in airports, train stations, and hospitals across 32 countries worldwide. While growth at UK travel hubs is likely to remain limited due to opposition on environmental grounds, the Asia-Pacific and Middle East regions are expected to lead the charge. I like this pivot, as the challenges WH Smith faced on the high street aren't nearly as strong in travel retail. At airports and train stations, there's a captive audience with time to kill and far fewer alternatives. No one's browsing Amazon (AMZN) for a bottle of water or the neck pillow they forgot to pack! Back in FY19, WH Smith reported revenue of £1.4bn and a £106m net profit. Then the pandemic hit the business like a sledgehammer, resulting in losses and higher debt. For FY26, which starts in September, revenue is expected to be £1.74bn, with a net profit of £114m. Yet the share price is still more than 50% lower than before Covid, despite the firm bouncing back strongly. Indeed, it's gone nowhere for five years now! Looking ahead, the company expects headline net debt to increase to £425m by August, above previous expectations for £400m. So the balance sheet is a risk worth watching. However, the stock looks cheap enough to consider, in my opinion. It's trading for less than 13 times forward earnings, while offering a 3% dividend yield. The post 1 sneaky UK growth stock to consider in July appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Ben McPoland has positions in Nvidia and Rolls-Royce Plc. The Motley Fool UK has recommended Amazon, Nvidia, Rolls-Royce Plc, and WH Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
an hour ago
- Associated Press
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
NEWCASTLE, England--(BUSINESS WIRE)--Jun 30, 2025-- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials. IKS014 is currently being investigated in an open-label phase 1 dose-escalation study ( ) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients. 'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.' The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026. About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ). About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on CONTACT: For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 [email protected] Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy Byrne Tel: +44 (0) 020 3727 1000 [email protected] KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Iksuda Therapeutics Copyright Business Wire 2025. PUB: 06/30/2025 08:00 PM/DISC: 06/30/2025 08:00 PM
